Thymalin
Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique
Completed
PHASE4
INTERVENTIONAL
NCT05040828
Early Intervention in Allergic Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
As many as 250 million people suffer from allergic rhinitis in China, which has a large population, early use of drugs may help better control the symptoms.This study aimed to investigate the effects of early interventional treatment with the leukotriene receptor antagonist (LTRA) montelukast on seasonal allergic rhinitis.
Interventions
Name:
Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.
Type:
BEHAVIORAL
Description:
Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Name:
Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.
Type:
BEHAVIORAL
Description:
10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Name:
No oral drug therapy throughout the pollen period
Type:
DRUG
Description:
Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
Primary Outcomes
Measure:
The change of subjective AR symptoms
TimeFrame:
baseline, visit 1: 2 weeks prior to the high weed pollen stage, visit 2: high weed pollen stage, visit 3: 2 weeks after the high weed pollen stage.
Description:
Symptom change before and after treatment was estimated by Visual analogue scale(VAS) symptom score. The VAS symptom scores ranged from 0 (asymptomatic) to 10 (very severe). The questionnaire included nasal symptoms: nasal congestion, nasal discharge, sneezing, and rhinocnesmus; eye symptoms: lacrimation, eye itching, eye redness, swelling, and ophthalmodynia; airway symptoms: wheezing, chest constriction, cough, labored breathing.
Trial Information
NCT ID
NCT05040828
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Beijing Tongren Hospital
Last Updated
December 15, 2025